Institutional members access full text with Ovid®

Maintenance therapy in ovarian cancer

Khalique, Sairaa; Hook, Jane M.b; Ledermann, Jonathan A.a,c

doi: 10.1097/CCO.0000000000000110
GYNECOLOGIC CANCER: Edited by Martin Gore

Purpose of review: Targeted therapies are being used as maintenance therapy to improve the outcome of ovarian cancer following standard treatment in the first-line setting and in recurrent disease. We review the different approaches being used, trial design, and the impact of maintenance treatment on survival and quality of life.

Recent findings: The greatest experience of maintenance therapy is with antiangiogenic agents. Several trials targeting vascular endothelial growth factor with bevacizumab or vascular endothelial growth factor receptor with oral tyrosine kinase inhibitors have demonstrated a prolongation in progression-free survival (PFS) following first or second-line treatment. Maintenance therapy with olaparib, a poly ADP ribose polymerase inhibitor given post-platinum therapy for recurrent disease, has led to a prolongation in PFS, particularly, in patients with a BRCA mutation. The results of immunotherapy maintenance studies, based on using cancer antigen 125 as an antigen, have been disappointing. A benefit in PFS often does not translate into overall survival improvement, largely because of crossover and postprogression therapies. This makes clinical interpretation of results more difficult.

Summary: The principle of using molecular targeted therapy to prolong the control of ovarian cancer has been clearly demonstrated. The greatest effect is on prolongation of PFS and, by adding to the effects of standard treatments, maintenance therapy is likely to help incrementally extend the 5-year survival of women with ovarian cancer.

aUCL Hospitals

bMedical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London (UCL)

cUCL Cancer Institute and UCL Hospitals, London, UK

Correspondence to Professor Jonathan A. Ledermann, UCL Cancer Institute, UCL and UCL Hospitals Comprehensive Biomedical Research Centre, 90 Tottenham Court Rd, London W1T 4TJ, UK. Tel: +44 20 7679 9898; e-mail: j.ledermann@ucl.ac.uk

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.co-oncology.com).

© 2014 Lippincott Williams & Wilkins, Inc.